These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 28581634)

  • 41. Hepatitis C Virus: Current and Evolving Treatments for Genotype 4.
    Asselah T; Bourlière M
    Gastroenterol Clin North Am; 2015 Dec; 44(4):859-70. PubMed ID: 26600224
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [A new challenge in clinical practice: resistance to directly acting antivirals in hepatitis C treatment].
    Chen ZW; Hu P; Ren H
    Zhonghua Gan Zang Bing Za Zhi; 2016 Mar; 24(3):165-9. PubMed ID: 27095757
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Clinical significance of drug resistance-associated mutations in treatment of hepatitis C with direct-acting antiviral agents].
    Li Z; Chen ZW; Ren H; Hu P
    Zhonghua Gan Zang Bing Za Zhi; 2017 Mar; 25(3):170-174. PubMed ID: 28482402
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Hepatitis C virus infection: Are there still specific problems with genotype 3?
    Gondeau C; Pageaux GP; Larrey D
    World J Gastroenterol; 2015 Nov; 21(42):12101-13. PubMed ID: 26576095
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Management of Hepatitis C Infection in children in the era of Direct-acting Antiviral Agents.
    Karnsakul W; Schwarz KB
    J Viral Hepat; 2019 Sep; 26(9):1034-1039. PubMed ID: 30980688
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Direct-acting antivirals for HCV treatment in older patients: A systematic review and meta-analysis.
    Villani R; Monami M; Di Cosimo F; Fioravanti G; Mannucci E; Vendemiale G; Serviddio G
    J Viral Hepat; 2019 Nov; 26(11):1249-1256. PubMed ID: 31243849
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Simplification of antiviral hepatitis C virus therapy to support expanded access in resource-limited settings.
    Ford N; Swan T; Beyer P; Hirnschall G; Easterbrook P; Wiktor S
    J Hepatol; 2014 Nov; 61(1 Suppl):S132-8. PubMed ID: 25443341
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Novel therapies for hepatitis C - one pill fits all?
    Manns MP; von Hahn T
    Nat Rev Drug Discov; 2013 Aug; 12(8):595-610. PubMed ID: 23807378
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Hepatitis C virus cell culture models: an encomium on basic research paving the road to therapy development.
    Lohmann V
    Med Microbiol Immunol; 2019 Feb; 208(1):3-24. PubMed ID: 30298360
    [TBL] [Abstract][Full Text] [Related]  

  • 50. PK/PD and antiviral activity of anti-HCV therapy: is there still a role in the choice of treatment?
    Zuccaro V; Lombardi A; Asperges E; Sacchi P; Bruno R
    Expert Opin Drug Metab Toxicol; 2020 Feb; 16(2):97-101. PubMed ID: 32003256
    [No Abstract]   [Full Text] [Related]  

  • 51. Rational Design and Adaptive Management of Combination Therapies for Hepatitis C Virus Infection.
    Ke R; Loverdo C; Qi H; Sun R; Lloyd-Smith JO
    PLoS Comput Biol; 2015 Jun; 11(6):e1004040. PubMed ID: 26125950
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Research progress of hepatitis C in 2018].
    Wei L
    Zhonghua Gan Zang Bing Za Zhi; 2019 Jan; 27(1):6-9. PubMed ID: 30685916
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Understanding the hepatitis C virus life cycle paves the way for highly effective therapies.
    Scheel TK; Rice CM
    Nat Med; 2013 Jul; 19(7):837-49. PubMed ID: 23836234
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Hepatitis C virus drug resistance-associated substitutions: State of the art summary.
    Lontok E; Harrington P; Howe A; Kieffer T; Lennerstrand J; Lenz O; McPhee F; Mo H; Parkin N; Pilot-Matias T; Miller V
    Hepatology; 2015 Nov; 62(5):1623-32. PubMed ID: 26095927
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Accurate hepatitis C virus genotyping and selection of optimal therapy: lessons from a St Petersburg strain infection.
    Knops E; Heger E; Koenig C; Moebius U; Lübke N; Kaiser R; Di Cristanziano V; Hüsgen L; Kocyigit C; Rupp J; Sierra S
    Clin Microbiol Infect; 2018 Apr; 24(4):440-441. PubMed ID: 29104172
    [No Abstract]   [Full Text] [Related]  

  • 56. Feasibility and acceptability of adherence support for direct acting antiviral therapy for hepatitis C in a low-threshold primary health-care opioid agonist treatment program.
    Chronister KJ; Lothian R; Gilliver R; Kearley J; Read P
    Drug Alcohol Rev; 2019 Feb; 38(2):185-189. PubMed ID: 30761640
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Direct-acting Antivirals for Hepatitis C and Implication for Community Pharmacy Practice.
    McEntee S; Liu Y; Mahmoudi T; Oliver K; Cadwell C
    Curr Pharm Des; 2023; 29(25):1967-1970. PubMed ID: 37584352
    [TBL] [Abstract][Full Text] [Related]  

  • 58. SHARED: An International Collaboration to Unravel Hepatitis C Resistance.
    Howe AYM; Ceccherini-Silberstein F; Dietz J; Popping S; Grebely J; Rodrigo C; Lennerstrand J; Douglas MW; Parczewsk M; Harrigan PR; Pawlotsky JM; Garcia F; Collaborators S
    Viruses; 2021 Aug; 13(8):. PubMed ID: 34452444
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A PDE multiscale model of hepatitis C virus infection can be transformed to a system of ODEs.
    Kitagawa K; Nakaoka S; Asai Y; Watashi K; Iwami S
    J Theor Biol; 2018 Jul; 448():80-85. PubMed ID: 29634960
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Required concentration index quantifies effective drug combinations against hepatitis C virus infection.
    Kakizoe Y; Koizumi Y; Ikoma Y; Ohashi H; Wakita T; Iwami S; Watashi K
    Theor Biol Med Model; 2021 Jan; 18(1):4. PubMed ID: 33422060
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.